Tuesday, April 28, 2009

Dendreon (DNDN) Hot Chart


Dendreon Corporation (DNDN). Did you own this stock? Well somebody did and it wasn't me. The stock has risen from the 4.25 area to the 22.50 area in the last 20 days.

Note: news due today at 2 PM eastern.

DNDN Chart

Dendreon Corporation (DNDN), a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.

Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is researching small molecule product candidates.

Dendreon Newsroom

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 agonist, D-3263, in Benign Prostatic Hyperplasia
Subscribe to All American Investor via Email



Bob DeMarco is a citizen journalist and twenty year Wall Street veteran. Bob has written more than 500 articles with more than 11,000 links to his work on the Internet. Content from All American Investor has been syndicated on Reuters, the Wall Street Journal, Fox News, Pluck, Blog Critics, and a growing list of newspaper websites. Bob is actively seeking syndication and writing assignments.


More from All American Investor





Follow All American Investor on Twitter